Cell Ageing Clocks From Blood Predict Alzheimer’s, ALS

Researchers have developed a machine learning framework that turns a single blood test into a set of cell-specific ageing clocks capable of predicting the risk of Alzheimer’s disease, ALS, lung cancer, type 2 diabetes and mortality up to 15 years in advance. Published in Nature Medicine and profiled in Cell Reports Medicine on 19 August 2026, the platform maps over 7,000 plasma proteins to more than 40 individual cell types.

The framework, developed by Ding et al., uses machine learning models trained to estimate cell-type-specific biological age from cell-enriched plasma protein abundance. Human Protein Atlas transcriptomic data mapped more than 7,000 plasma proteins to over 40 cell types. The models were validated across nearly 60,000 individuals from three major cohorts (Global Neurodegeneration Proteomics Consortium, UK Biobank and 1946 National Survey of Health and Development), with replication across SomaScan and Olink proteomic platforms. The approach treats circulating proteins as tissue-specific signals, adding functional risk stratification beyond conventional static genetic assessments.

The strongest predictive signal was extreme astrocyte ageing for incident Alzheimer’s disease (hazard ratio 12.59 over 15 years in the UK Biobank), well ahead of APOE4 carrier status (5.30) and chronological age (1.24). Among APOE4/4 homozygotes, cumulative AD incidence was 38.3% in extreme astrocyte agers versus 0% in youthful astrocyte profiles. The framework also linked extreme skeletal myocyte ageing to ALS (HR 12.7), alveolar cell ageing to lung cancer (HR 8.39) and myeloid-lineage ageing to type 2 diabetes. A composite Polycellular Aging Risk Score showed 15-year survival falling from ~90% in normal agers to ~34% in individuals with extreme ageing across 20+ cell types.

The commercial signal is a rapidly maturing precision medicine proteomics market where cellular ageing clocks unlock significant patient stratification and preclinical drug development opportunities. Alongside recent Alzheimer’s and Parkinson’s proteomics initiatives, this framework strengthens the case for large-scale plasma proteomics platforms. Expect Olink (Thermo Fisher), Standard BioTools (SomaLogic), Quanterix and Alamar Biosciences to sharpen their positioning through late 2026 and 2027.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!